文献速递免疫规划卫生政策与健康促进

高价肺炎球菌结合疫苗在美国老年人中的探索性成本效果分析

Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors.
PubMed 文献 · Am J Prev Med · 2021-04-29

该研究用马尔可夫模型评估美国≥65岁老年人使用现有及在研肺炎球菌结合疫苗的成本效果。基线假设下单独使用20价疫苗相比现行推荐每获得一个质量调整生命年需172,491美元,考虑儿童接种的间接效应后15价或20价疫苗每QALY成本超过449,000美元。结论认为在研高价结合疫苗在老年人中经济性可能不合理。

要点

  • 基线假设下单独使用20价疫苗每QALY成本为172,491美元。
  • 考虑间接效应后15价或20价疫苗每QALY成本超过449,000美元。
  • 含儿童疫苗未覆盖高危血清型的成人疫苗可能更有前景。

核心结论

  • 在研肺炎球菌结合疫苗在美国老年人中经济性可能不合理,无论血清型有效性假设如何,尤其考虑儿童接种的间接效应时。
  • 含儿童疫苗未覆盖高危血清型的成人疫苗可能更有前景。

研究设计与样本

  • 马尔可夫模型评估美国现行推荐及替代策略使用现有和在研肺炎球菌结合疫苗在老年人中的成本效果。
  • 数据收集与分析于2020年进行,并进行了敏感性分析和替代情景分析。

主要发现

  • 仅考虑现有和在研疫苗时,基线假设下单独使用20价疫苗相比现行美国推荐每QALY成本为172,491美元。
  • 使用15价疫苗的策略成本更高且效果更差。
  • 假设13价/20价疫苗对血清型3无效而15价疫苗完全有效时,15价疫苗每QALY成本为237,431美元。
  • 考虑间接效应时,15价或20价疫苗每QALY成本超过449,000美元。
  • 基线假设下添加假设性20价疫苗每QALY成本为139,348美元。

临床怎么用

  • 老年肺炎球菌疫苗接种决策需结合成本效果证据,尤其考虑儿童接种的间接效应。
  • 含儿童疫苗未覆盖高危血清型的成人疫苗可能更具经济性前景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Use of the 13-valent pneumococcal conjugate vaccine in nonimmunocompromised adults aged ≥65 years is controversial. Higher-valency conjugate vaccines (15-valent and 20-valent ) are under development; their potential cost effectiveness in older adults is unknown, particularly when potential indirect (herd immunity) effects from childhood vaccination are considered. METHODS: A Markov model estimated the cost effectiveness of current U.S. recommendations and alternative strategies using currently available and in-development pneumococcal conjugate vaccines in seniors. Separately, strategies using a hypothetical 20-valent vaccine adding the 7 most common disease-causing non-13-valent vaccine serotypes were considered. Sensitivity analyses were performed and alternative scenarios were examined. Data were gathered and the analyses were performed in 2020. RESULTS: In analyses considering only existing and in-development vaccines, sole 20-valent vaccine use cost $172,491/quality-adjusted life year gained compared with current U.S. recommendations under baseline assumptions (equal serotype effectiveness and no childhood vaccination indirect effects). Strategies using 15-valent vaccine were more costly and less effective. When 13-valent/20-valent vaccines were assumed ineffective against pneumococcal serotype 3 and 15-valent vaccine was fully effective, 15-valent vaccine cost $237,431/quality-adjusted life year gained. With indirect effects considered, 15-valent or 20-valent vaccine cost >$449,000/quality-adjusted life year gained. When adding hypothetical 20-valent vaccine under baseline assumptions, hypothetical 20-valent vaccine cost $139,348/quality-adjusted life year gained. CONCLUSIONS: In-development pneumococcal conjugate vaccines may be economically unreasonable in older adults, regardless of serotype effectiveness assumptions, particularly when considering potential indirect effects from use of those vaccines in children. Adult vaccines containing high-risk serotypes not contained in childhood vaccines may be more promising.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Smith KJ, Wateska AR, Nowalk MP, et al. Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. Am J Prev Med. 2021. PMID: 34148625. doi:10.1016/j.amepre.2021.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。